Summary
Arterial infusion chemotherapy of EPF (etoposide, cisplatin, and 5-fluorouracil) or EAP (etoposide, Adriamycin, and cisplatin) was carried out in 28 cases of advanced hepatocellular carcinoma (HCC) between January 1988 and December 1990, and assessment was made of the anticancer efficacy of each treatment method. In all, 13 patients were treated with EPF therapy and 15 received EAP therapy. The anticancer agents were infused through a catheter inserted into the proper or common hepatic artery. The catheter was inserted via the axillary artery or common femoral artery using Seldinger's method or the cut-down method. The results of each therapy were analyzed in relation to the tumor regression rate and the side effects encountered. The tumor regression rate was determined on the basis of two-dimensional evidence obtained by computed tomography performed before and after treatment. The treatment results were also compared with the results of chemoembolization therapy using a mixture of cisplatin (CDDP), Adriamycin (ADM) and lipiodol. Of the 28 patients treated with arterial infusion chemotherapy, 14 (50%) attained a regression rate of 50% (PR). In all, 46% of the EPF group and 53% of the EAP group achieved a PR. These results were superior to those obtained using chemoembolization therapy. In general, the side effects were relatively mild and transient.
Similar content being viewed by others
References
Fujii N, Yodono H, Sasaki T, Tarusawa K, Kanehira J, Takahashi S, Akimura R, Takekawa S (1989) New technique of intra-arterial catheterization via the branch of left axillary artery for continuous infusion chemotherapy. Nippon Acta Radiol 49: 684
Liver Cancer Study Group of Japan (1987) The general rules for the clinical and pathological study of primary liver cancer (in Japanese). Kanehara Shuppan, Tokyo
Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP16 with Adriamycin. Cancer 51: 206
Quinn JJ, Altman AJ, Robinson T, Cooke RW, Hight DW, Foster JH (1985) Adriamycin and cisplatin for hepatoblastoma. Cancer 56: 1926
Sato Y, Fujiwara K, Ogata I, Ohta Y, Hayashi S, Oka Y, Furui S, Oka H (1985) Transcatheter arterial embrolization for hepatocellular carcinoma. Benefits and limitations for unresectable cases with liver cirrhosis evaluated by comparison with other conservative treatments. Cancer 55: 2822
Tarusawa K, Yodono H, Sasaki T, Ikami I, Fujii N, Akimura R, Nakamura K, Kanehira J, Midorikawa H, Kimura T, Momose A, Shibutani K, Takekawa SD (1990) Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU. Jpn J Cancer Chemother 17: 53
Tsushima K, Suzuki H, Kimura T, Sakata Y, Sasaki D, Yoshida Y, Komatsu Y, Sugawara K, Yodono H, Nara H (1984) The combination chemotherapy of mitomycin-C, carboquone, 5-fluorouracil and OK-432 against inoperable liver cancer—including the method of intra-arterial administration of MMC and CQ. Hirosaki Med J 36: 590
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397
Yodono H, Tarusawa K, Sasaki T, Kanehira J, Saito Y, Takahashi S, Kimura T, Nishi N, Nakamura Y, Takekawa S (1989) A case with hepatocellular carcinoma effectively treated by intra-arterial infusion of CDDP and other agents. Jpn J Cancer Chemother 16: 3265
Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa S (1989) Combination chemoembolization therapy for hepatocellular carcinoma, mainly using cisplatin (CDDP). Cancer Chemother Pharmacol 23 [Suppl]: S42
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yodono, H., Sasaki, T., Tarusawa, K. et al. Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother. Pharmacol. 31 (Suppl 1), S89–S92 (1992). https://doi.org/10.1007/BF00687114
Issue Date:
DOI: https://doi.org/10.1007/BF00687114